119 related articles for article (PubMed ID: 12529458)
21. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
22. [Hematopoietic malignancies and gene therapy].
Ozawa K
Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
[TBL] [Abstract][Full Text] [Related]
23. Is retroviral gene marking too dangerous to use?
Brenner MK; Heslop HE
Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996
[No Abstract] [Full Text] [Related]
24. Gene therapy fulfilling its promise.
Kohn DB; Candotti F
N Engl J Med; 2009 Jan; 360(5):518-21. PubMed ID: 19179320
[No Abstract] [Full Text] [Related]
25. For gene therapy, now-quantified risks are deemed troubling.
Twombly R
J Natl Cancer Inst; 2003 Jul; 95(14):1032-3. PubMed ID: 12865444
[No Abstract] [Full Text] [Related]
26. Gene therapists hopeful as trials resume with childhood disease.
Check E
Nature; 2004 Jun; 429(6992):587. PubMed ID: 15190314
[No Abstract] [Full Text] [Related]
27. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
28. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy. What to do when clear success comes with an unclear risk?
Marshall E
Science; 2002 Oct; 298(5593):510-1. PubMed ID: 12386304
[No Abstract] [Full Text] [Related]
30. [The current status of gene therapy in severe immunodeficiency].
Winckler T
Pharm Unserer Zeit; 2009; 38(3):204-6. PubMed ID: 19396911
[No Abstract] [Full Text] [Related]
31. [Methodology of gene therapy: adverse events and further technological developments].
Hamada H
Nihon Rinsho; 2010 Aug; 68 Suppl 8():601-6. PubMed ID: 20979308
[No Abstract] [Full Text] [Related]
32. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
Cichutek K
Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
[No Abstract] [Full Text] [Related]
33. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
Hacein-Bey-Abina S; Le Deist F; Carlier F; Bouneaud C; Hue C; De Villartay JP; Thrasher AJ; Wulffraat N; Sorensen R; Dupuis-Girod S; Fischer A; Davies EG; Kuis W; Leiva L; Cavazzana-Calvo M
N Engl J Med; 2002 Apr; 346(16):1185-93. PubMed ID: 11961146
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy. Second child in French trial is found to have leukemia.
Marshall E
Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
[No Abstract] [Full Text] [Related]
35. [Setback for gene therapy: Two cases of leukemia in a French trial].
Richter J; Relander T; Fasth A; Karlsson S
Lakartidningen; 2003 Feb; 100(7):498-500. PubMed ID: 12640983
[No Abstract] [Full Text] [Related]
36. Gene therapy. Panel urges limits on X-SCID trials.
Kaiser J
Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
[No Abstract] [Full Text] [Related]
37. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
Kaiser J
Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
[No Abstract] [Full Text] [Related]
38. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
39. Genes can come true.
Phillips H
New Sci; 2002 Nov; 176(2371):30-3. PubMed ID: 12731520
[No Abstract] [Full Text] [Related]
40. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]